Bassan M, Weiler-Ravell D, Shalev O
Br Med J (Clin Res Ed). 1982 Apr 10;284(6322):1067-70. doi: 10.1136/bmj.284.6322.1067.
Ten men with stable angina pectoris not fully relieved by optimal doses of propranolol (mean 218 mg daily) were given a single oral dose of 120 mg verapamil or a placebo on alternate mornings; the order of treatment was double blind. Patients had trained in a protocol that precipitated angina after three to six minutes of exercise on a bicycle ergometer. On test days, and with continued propranolol treatment, bicycle exercise was performed just before the administration of verapamil or placebo and hourly thereafter for eight hours. Mean exercise tolerance was 118 seconds greater one hour after verapamil than one hour after placebo (p <0.001), and a significant though somewhat diminished difference of 66 seconds was still present at six hours (p <0.01). Verapamil lowered resting systolic blood pressure by 12 mm Hg (p <0.01) without changing heart rate. None of the 10 patients showed adverse effects from the verapamil-propranolol combination.The results of this study suggest that verapamil is a highly effective antianginal supplement to propranolol.
10名患有稳定型心绞痛且使用最佳剂量普萘洛尔(平均每日218毫克)后症状仍未完全缓解的男性患者,每隔一天的早晨接受一次120毫克维拉帕米的单次口服给药或安慰剂治疗;治疗顺序采用双盲法。患者按照一项方案进行训练,即在自行车测力计上运动三到六分钟后诱发心绞痛。在测试日,继续使用普萘洛尔治疗,在服用维拉帕米或安慰剂之前进行自行车运动,之后每小时进行一次,持续八小时。维拉帕米给药后一小时的平均运动耐量比安慰剂给药后一小时长118秒(p<0.001),六小时时仍存在显著差异(虽有所减小),为66秒(p<0.01)。维拉帕米使静息收缩压降低了12毫米汞柱(p<0.01),心率未改变。10名患者中无一例显示出维拉帕米与普萘洛尔联合使用的不良反应。本研究结果表明,维拉帕米是普萘洛尔的一种高效抗心绞痛补充药物。